Annual Revenue
$8.95 M
-$5.76 M-39.16%
31 December 2023
Summary:
Lineage Cell Therapeutics annual revenue is currently $8.95 million, with the most recent change of -$5.76 million (-39.16%) on 31 December 2023. During the last 3 years, it has risen by +$8.17 million (+1057.18%). LCTX annual revenue is now -39.16% below its all-time high of $14.70 million, reached on 31 December 2022.LCTX Revenue Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Revenue
$3.78 M
+$2.37 M+168.39%
30 September 2024
Summary:
Lineage Cell Therapeutics quarterly revenue is currently $3.78 million, with the most recent change of +$2.37 million (+168.39%) on 30 September 2024. Over the past year, it has increased by +$2.53 million (+203.29%). LCTX quarterly revenue is now -27.84% below its all-time high of $5.24 million, reached on 31 March 2022.LCTX Quarterly Revenue Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM Revenue
$8.72 M
+$2.53 M+40.95%
30 September 2024
Summary:
Lineage Cell Therapeutics TTM revenue is currently $8.72 million, with the most recent change of +$2.53 million (+40.95%) on 30 September 2024. Over the past year, it has dropped by -$53.00 thousand (-0.60%). LCTX TTM revenue is now -40.70% below its all-time high of $14.70 million, reached on 31 December 2022.LCTX TTM Revenue Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
LCTX Revenue Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -39.2% | +203.3% | -0.6% |
| 3 y3 years | +1057.2% | +71.6% | +181.1% |
| 5 y5 years | +531.7% | +1641.5% | +967.2% |
LCTX Revenue High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -39.2% | +1057.2% | -27.8% | +293.6% | -40.7% | +181.1% |
| 5 y | 5 years | -39.2% | +1057.2% | -27.8% | +3717.2% | -40.7% | +1027.9% |
| alltime | all time | -39.2% | -27.8% | +438.8% | -40.7% | >+9999.0% |
Lineage Cell Therapeutics Revenue History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $3.78 M(+168.4%) | $8.72 M(+40.9%) |
| June 2024 | - | $1.41 M(-2.5%) | $6.19 M(-22.7%) |
| Mar 2024 | - | $1.44 M(-30.8%) | $8.00 M(-10.5%) |
| Dec 2023 | $8.95 M(-39.2%) | $2.09 M(+67.6%) | $8.95 M(+2.0%) |
| Sept 2023 | - | $1.25 M(-61.4%) | $8.77 M(-16.6%) |
| June 2023 | - | $3.23 M(+35.2%) | $10.52 M(-11.2%) |
| Mar 2023 | - | $2.39 M(+24.6%) | $11.85 M(-19.4%) |
| Dec 2022 | $14.70 M(+277.4%) | $1.92 M(-36.1%) | $14.70 M(+6.9%) |
| Sept 2022 | - | $3.00 M(-34.2%) | $13.75 M(+6.1%) |
| June 2022 | - | $4.55 M(-13.1%) | $12.95 M(+46.5%) |
| Mar 2022 | - | $5.24 M(+445.5%) | $8.84 M(+126.9%) |
| Dec 2021 | $3.90 M(+404.0%) | $960.00 K(-56.4%) | $3.90 M(+25.6%) |
| Sept 2021 | - | $2.20 M(+399.3%) | $3.10 M(+149.8%) |
| June 2021 | - | $441.00 K(+50.5%) | $1.24 M(+38.0%) |
| Mar 2021 | - | $293.00 K(+76.5%) | $900.00 K(+16.4%) |
| Dec 2020 | $773.00 K(-47.7%) | $166.00 K(-51.5%) | $773.00 K(-46.3%) |
| Sept 2020 | - | $342.00 K(+245.5%) | $1.44 M(+9.5%) |
| June 2020 | - | $99.00 K(-40.4%) | $1.31 M(-10.3%) |
| Mar 2020 | - | $166.00 K(-80.0%) | $1.47 M(-0.9%) |
| Dec 2019 | $1.48 M(+4.4%) | $832.00 K(+283.4%) | $1.48 M(+80.9%) |
| Sept 2019 | - | $217.00 K(-13.2%) | $817.00 K(-5.4%) |
| June 2019 | - | $250.00 K(+39.7%) | $864.00 K(-29.2%) |
| Mar 2019 | - | $179.00 K(+4.7%) | $1.22 M(-13.8%) |
| Dec 2018 | $1.42 M(-21.0%) | $171.00 K(-35.2%) | $1.42 M(-21.9%) |
| Sept 2018 | - | $264.00 K(-56.4%) | $1.81 M(-9.9%) |
| June 2018 | - | $606.00 K(+61.6%) | $2.01 M(+12.6%) |
| Mar 2018 | - | $375.00 K(-34.1%) | $1.79 M(-0.2%) |
| Dec 2017 | $1.79 M(-20.4%) | $569.00 K(+22.9%) | $1.79 M(-9.5%) |
| Sept 2017 | - | $463.00 K(+21.5%) | $1.98 M(+3.8%) |
| June 2017 | - | $381.00 K(+0.5%) | $1.91 M(-6.1%) |
| Mar 2017 | - | $379.00 K(-50.0%) | $2.03 M(-9.2%) |
| Dec 2016 | $2.25 M(-11.1%) | $758.00 K(+94.4%) | $2.24 M(+10.0%) |
| Sept 2016 | - | $390.00 K(-22.9%) | $2.04 M(-18.1%) |
| June 2016 | - | $506.00 K(-13.7%) | $2.49 M(-2.6%) |
| Mar 2016 | - | $586.00 K(+5.6%) | $2.55 M(+0.8%) |
| Dec 2015 | $2.53 M(+30.1%) | $555.00 K(-33.9%) | $2.53 M(+4.5%) |
| Sept 2015 | - | $840.00 K(+46.9%) | $2.42 M(+14.0%) |
| June 2015 | - | $572.00 K(+1.2%) | $2.13 M(+5.2%) |
| Mar 2015 | - | $565.00 K(+27.0%) | $2.02 M(+3.8%) |
| Dec 2014 | $1.95 M(-31.9%) | $445.00 K(-18.0%) | $1.95 M(-29.5%) |
| Sept 2014 | - | $543.00 K(+16.3%) | $2.76 M(-0.4%) |
| June 2014 | - | $467.00 K(-4.9%) | $2.77 M(-2.0%) |
| Mar 2014 | - | $491.00 K(-61.0%) | $2.83 M(-1.2%) |
| Dec 2013 | $2.86 M(+69.0%) | $1.26 M(+127.7%) | $2.86 M(+35.0%) |
| Sept 2013 | - | $553.60 K(+5.9%) | $2.12 M(-0.4%) |
| June 2013 | - | $522.80 K(-0.2%) | $2.13 M(+8.2%) |
| Mar 2013 | - | $524.10 K(+1.1%) | $1.97 M(+16.1%) |
| Dec 2012 | $1.69 M(+1.6%) | $518.20 K(-7.8%) | $1.69 M(+2773.7%) |
| Sept 2012 | - | $561.90 K(+55.6%) | $58.90 K(-91.1%) |
| June 2012 | - | $361.10 K(+43.6%) | $658.60 K(-38.9%) |
| Mar 2012 | - | $251.40 K(-122.5%) | $1.08 M(-34.7%) |
| Dec 2011 | $1.67 M(+21.5%) | -$1.12 M(-196.0%) | $1.65 M(-12.0%) |
| Sept 2011 | - | $1.16 M(+48.8%) | $1.88 M(+22.6%) |
| June 2011 | - | $780.40 K(-5.4%) | $1.53 M(+7.0%) |
| Mar 2011 | - | $824.60 K(-192.7%) | $1.43 M(+4.1%) |
| Dec 2010 | $1.37 M(-28.8%) | -$889.70 K(-209.1%) | $1.37 M(-54.4%) |
| Sept 2010 | - | $815.30 K(+19.8%) | $3.01 M(+13.9%) |
| June 2010 | - | $680.30 K(-11.4%) | $2.64 M(+10.4%) |
| Mar 2010 | - | $768.10 K(+2.5%) | $2.40 M(+24.5%) |
| Dec 2009 | $1.93 M(+28.0%) | $749.30 K(+67.6%) | $1.93 M(+31.8%) |
| Sept 2009 | - | $447.00 K(+3.4%) | $1.46 M(+1.4%) |
| June 2009 | - | $432.10 K(+45.6%) | $1.44 M(+1.5%) |
| Mar 2009 | - | $296.70 K(+4.0%) | $1.42 M(-5.6%) |
| Dec 2008 | $1.50 M | $285.30 K(-33.2%) | $1.50 M(-4.6%) |
| Sept 2008 | - | $426.90 K(+4.0%) | $1.58 M(+14.2%) |
| June 2008 | - | $410.60 K(+7.8%) | $1.38 M(+16.9%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2008 | - | $381.00 K(+6.3%) | $1.18 M(+12.9%) |
| Dec 2007 | $1.05 M(-10.0%) | $358.50 K(+55.1%) | $1.05 M(-10.4%) |
| Sept 2007 | - | $231.20 K(+9.7%) | $1.17 M(-5.3%) |
| June 2007 | - | $210.70 K(-14.2%) | $1.23 M(+5.8%) |
| Mar 2007 | - | $245.70 K(-48.8%) | $1.17 M(+0.3%) |
| Dec 2006 | $1.16 M(+28.7%) | $480.10 K(+61.6%) | $1.16 M(+28.5%) |
| Sept 2006 | - | $297.00 K(+107.4%) | $904.30 K(+6.7%) |
| June 2006 | - | $143.20 K(-40.8%) | $847.70 K(-11.1%) |
| Mar 2006 | - | $241.70 K(+8.7%) | $953.80 K(+5.6%) |
| Dec 2005 | $903.20 K(+31.2%) | $222.40 K(-7.5%) | $903.20 K(+3.5%) |
| Sept 2005 | - | $240.40 K(-3.6%) | $872.80 K(+8.7%) |
| June 2005 | - | $249.30 K(+30.5%) | $802.80 K(+7.2%) |
| Mar 2005 | - | $191.10 K(-0.5%) | $748.80 K(+8.8%) |
| Dec 2004 | $688.40 K(+23.7%) | $192.00 K(+12.7%) | $688.40 K(-8.1%) |
| Sept 2004 | - | $170.40 K(-12.7%) | $749.00 K(+8.8%) |
| June 2004 | - | $195.30 K(+49.4%) | $688.50 K(+16.6%) |
| Mar 2004 | - | $130.70 K(-48.3%) | $590.50 K(+6.1%) |
| Dec 2003 | $556.40 K(+43.8%) | $252.60 K(+129.8%) | $556.40 K(+14.3%) |
| Sept 2003 | - | $109.90 K(+12.9%) | $486.90 K(+5.2%) |
| June 2003 | - | $97.30 K(+0.7%) | $462.80 K(+8.6%) |
| Mar 2003 | - | $96.60 K(-47.2%) | $426.30 K(+10.2%) |
| Dec 2002 | $387.00 K(+154.8%) | $183.10 K(+113.4%) | $386.90 K(+50.8%) |
| Sept 2002 | - | $85.80 K(+41.1%) | $256.60 K(+23.8%) |
| June 2002 | - | $60.80 K(+6.3%) | $207.20 K(+17.5%) |
| Mar 2002 | - | $57.20 K(+8.3%) | $176.40 K(+16.1%) |
| Dec 2001 | $151.90 K(+189.3%) | $52.80 K(+45.1%) | $151.90 K(+0.2%) |
| Sept 2001 | - | $36.40 K(+21.3%) | $151.60 K(+31.6%) |
| June 2001 | - | $30.00 K(-8.3%) | $115.20 K(+24.4%) |
| Mar 2001 | - | $32.70 K(-37.7%) | $92.60 K(+41.2%) |
| Dec 2000 | $52.50 K(-94.9%) | $52.50 K(>+9900.0%) | $65.60 K(+29.6%) |
| Sept 2000 | - | $0.00(-100.0%) | $50.60 K(0.0%) |
| June 2000 | - | $7400.00(+29.8%) | $50.60 K(-92.1%) |
| Mar 2000 | - | $5700.00(-84.8%) | $643.20 K(-38.0%) |
| Dec 1999 | $1.04 M(>+9900.0%) | $37.50 K(>+9900.0%) | $1.04 M(+3.8%) |
| Sept 1999 | - | $0.00(-100.0%) | $1.00 M(-9.1%) |
| June 1999 | - | $600.00 K(+50.0%) | $1.10 M(+4.8%) |
| Mar 1999 | - | $400.00 K(+300.0%) | $1.05 M(-8.7%) |
| Dec 1998 | $0.00(-100.0%) | - | - |
| Sept 1998 | - | $100.00 K(-81.8%) | $1.15 M(0.0%) |
| June 1998 | - | $550.00 K(+450.0%) | $1.15 M(+91.7%) |
| June 1998 | $1.15 M(+1050.0%) | - | - |
| Mar 1998 | - | $100.00 K(-75.0%) | $600.00 K(0.0%) |
| Dec 1997 | - | $400.00 K(+300.0%) | $600.00 K(+100.0%) |
| Sept 1997 | - | $100.00 K(0.0%) | $300.00 K(0.0%) |
| June 1997 | $100.00 K(0.0%) | - | - |
| Mar 1997 | - | $100.00 K(0.0%) | $300.00 K(0.0%) |
| Dec 1996 | - | $100.00 K(0.0%) | $300.00 K(0.0%) |
| Sept 1996 | - | $100.00 K(0.0%) | $300.00 K(0.0%) |
| June 1996 | $100.00 K(0.0%) | - | - |
| Mar 1996 | - | $100.00 K(0.0%) | $300.00 K(0.0%) |
| Dec 1995 | - | $100.00 K(0.0%) | $300.00 K(0.0%) |
| Sept 1995 | - | $100.00 K(0.0%) | $300.00 K(0.0%) |
| June 1995 | $100.00 K(0.0%) | - | - |
| Mar 1995 | - | $100.00 K(0.0%) | $300.00 K(0.0%) |
| Dec 1994 | - | $100.00 K(0.0%) | $300.00 K(0.0%) |
| Sept 1994 | - | $100.00 K(0.0%) | $300.00 K(0.0%) |
| June 1994 | $100.00 K(0.0%) | - | - |
| Mar 1994 | - | $100.00 K(0.0%) | $300.00 K(0.0%) |
| Dec 1993 | - | $100.00 K(0.0%) | $300.00 K(0.0%) |
| Sept 1993 | - | $100.00 K(0.0%) | $300.00 K(0.0%) |
| June 1993 | $100.00 K(0.0%) | - | - |
| Mar 1993 | - | $100.00 K(0.0%) | $300.00 K(0.0%) |
| Dec 1992 | - | $100.00 K(0.0%) | $300.00 K(+50.0%) |
| Sept 1992 | - | $100.00 K(0.0%) | $200.00 K(+100.0%) |
| June 1992 | $100.00 K | - | - |
| Mar 1992 | - | $100.00 K | $100.00 K |
FAQ
- What is Lineage Cell Therapeutics annual revenue?
- What is the all time high annual revenue for Lineage Cell Therapeutics?
- What is Lineage Cell Therapeutics annual revenue year-on-year change?
- What is Lineage Cell Therapeutics quarterly revenue?
- What is the all time high quarterly revenue for Lineage Cell Therapeutics?
- What is Lineage Cell Therapeutics quarterly revenue year-on-year change?
- What is Lineage Cell Therapeutics TTM revenue?
- What is the all time high TTM revenue for Lineage Cell Therapeutics?
- What is Lineage Cell Therapeutics TTM revenue year-on-year change?
What is Lineage Cell Therapeutics annual revenue?
The current annual revenue of LCTX is $8.95 M
What is the all time high annual revenue for Lineage Cell Therapeutics?
Lineage Cell Therapeutics all-time high annual revenue is $14.70 M
What is Lineage Cell Therapeutics annual revenue year-on-year change?
Over the past year, LCTX annual revenue has changed by -$5.76 M (-39.16%)
What is Lineage Cell Therapeutics quarterly revenue?
The current quarterly revenue of LCTX is $3.78 M
What is the all time high quarterly revenue for Lineage Cell Therapeutics?
Lineage Cell Therapeutics all-time high quarterly revenue is $5.24 M
What is Lineage Cell Therapeutics quarterly revenue year-on-year change?
Over the past year, LCTX quarterly revenue has changed by +$2.53 M (+203.29%)
What is Lineage Cell Therapeutics TTM revenue?
The current TTM revenue of LCTX is $8.72 M
What is the all time high TTM revenue for Lineage Cell Therapeutics?
Lineage Cell Therapeutics all-time high TTM revenue is $14.70 M
What is Lineage Cell Therapeutics TTM revenue year-on-year change?
Over the past year, LCTX TTM revenue has changed by -$53.00 K (-0.60%)